Home Cardiorenal Module Case 25 HFpEF Roundtable

Heart Failure, Diuretic Resistance & Volume Management

Cardiorenal Syndrome, Neurohormonal Pathophysiology, and Strategies to Overcome Diuretic Resistance

Cardiorenal Syndrome Diuretic Resistance Volume Assessment GDMT Escalation Strategies

Quick Navigation

Cardiorenal Syndrome Neurohormonal Activation Diuretic Resistance Spot Urine Sodium Escalation Ladder Volume Assessment GDMT in CRS When to Refer

Cardiorenal Syndrome: Classification

Cardiorenal syndrome (CRS) describes the bidirectional pathophysiologic interactions between the heart and kidneys whereby acute or chronic dysfunction of one organ induces dysfunction of the other.

1

Acute Cardiorenal

Heart → Kidney

Acute heart failure (ADHF) causes acute kidney injury

Example: Cardiogenic shock with AKI; acute decompensated HF with rising creatinine

2

Chronic Cardiorenal

Heart → Kidney

Chronic heart failure causes progressive CKD

Example: Chronic low cardiac output leading to progressive renal dysfunction

3

Acute Renocardiac

Kidney → Heart

Acute kidney injury causes acute cardiac dysfunction

Example: AKI with hyperkalemia causing arrhythmias; volume overload causing pulmonary edema

4

Chronic Renocardiac

Kidney → Heart

CKD causes chronic cardiac dysfunction

Example: CKD causing LVH, accelerated atherosclerosis, cardiomyopathy

5

Secondary CRS

Systemic disease → Both

Systemic conditions cause simultaneous cardiac and renal dysfunction

Examples: Diabetes, sepsis, amyloidosis, sarcoidosis

Clinical Pearl: Types 1 and 2 (cardiorenal) are most commonly encountered in clinical practice. In Type 1 CRS, the dilemma is whether rising creatinine during ADHF treatment represents worsening renal perfusion (requiring less diuresis) or effective decongestion (allow creatinine to rise while continuing to diurese). Venous congestion, not low cardiac output, is the primary driver of renal dysfunction in most ADHF cases.

Neurohormonal Activation in Heart Failure

Heart failure triggers compensatory neurohormonal responses that initially maintain perfusion but become maladaptive over time, driving disease progression.

RAAS Activation

Trigger: Reduced renal perfusion → renin release

  • Angiotensin II: vasoconstriction, aldosterone secretion, sodium retention
  • Aldosterone: Na/H2O retention, K wasting, cardiac fibrosis
  • Creates positive feedback loop worsening congestion

Therapeutic targets: ACEi, ARB, ARNI, MRA

Sympathetic Nervous System

Trigger: Baroreceptor sensing of low CO

  • Increased heart rate and contractility
  • Peripheral vasoconstriction
  • Renal vasoconstriction (reduced RBF)
  • Stimulates renin release
  • Chronic activation: myocyte toxicity, arrhythmias

Therapeutic targets: Beta-blockers

ADH / Vasopressin

Trigger: Non-osmotic release from low effective circulating volume

  • V2 receptor: water reabsorption in collecting duct
  • V1a receptor: vasoconstriction
  • Causes dilutional hyponatremia
  • Maintains effectiveness even in advanced HF

Clinical marker: Hyponatremia predicts poor prognosis

Natriuretic Peptides (BNP/ANP)

Trigger: Atrial/ventricular wall stretch

  • Counter-regulatory: natriuresis, vasodilation, RAAS inhibition
  • Initially protective
  • Resistance develops with disease progression
  • Receptor downregulation, enhanced degradation by neprilysin

Therapeutic targets: ARNI (sacubitril/valsartan)

Key Concept: As HF progresses, BNP loses effectiveness (receptor downregulation, increased neprilysin degradation), while aldosterone and ADH maintain or increase their biological importance. This shifting balance explains why RAAS blockade and MRAs remain effective in advanced HF, while strategies solely enhancing natriuretic peptides show diminishing returns.

Diuretic Resistance: Mechanisms

Definition: Failure to achieve adequate decongestion despite escalating diuretic doses. Functionally, an inadequate natriuretic response to appropriate doses of loop diuretics.

Mechanisms of Diuretic Resistance

Post-Diuretic Na Retention

After diuretic wears off, compensatory Na reabsorption occurs in distal nephron segments, negating earlier natriuresis

Braking Phenomenon

Chronic loop diuretic use causes distal tubular hypertrophy with increased Na/K-ATPase activity and NCC expression, limiting net sodium excretion

Gut Edema

Intestinal wall edema reduces oral furosemide absorption (bioavailability drops from 40–60% to <20%). Bowel wall thickness correlates with poor oral diuretic response

Hypoalbuminemia

Furosemide is >95% albumin-bound. Low albumin increases Vd, reduces delivery to proximal tubule OAT for secretion. Most significant when albumin <2.0 g/dL

Reduced Renal Perfusion

Low cardiac output and/or elevated venous congestion reduce renal blood flow and GFR, decreasing diuretic delivery to tubular site of action

RAAS Activation

Diuretics activate RAAS, which promotes sodium and water retention, partially counteracting diuretic effect

Gut Edema and Oral Diuretic Failure

Why Furosemide Fails Orally in ADHF

  • Baseline oral bioavailability: only 40–60% (highly variable)
  • Gut wall edema further reduces absorption
  • Delayed gastric emptying and reduced splanchnic perfusion
  • Colonic wall thickness ≥3 mm correlates with poor oral response

Advantages of Bumetanide and Torsemide

  • Bumetanide: 80% oral bioavailability (vs. 40% furosemide); less affected by gut edema due to higher lipid solubility and passive diffusion
  • Torsemide: >90% bioavailability even in HF, renal insufficiency, and cirrhosis; longest half-life; most predictable absorption
  • Consider switching from furosemide if poor oral response
Albumin-Furosemide Co-administration: When albumin <2.0 g/dL, consider co-administering 25–50g IV albumin with furosemide. Albumin traps furosemide in plasma for delivery to renal OAT transporters. Most effective when albumin <2.0 g/dL (strong evidence); moderate evidence for 2.0–2.5 g/dL; no benefit when albumin >2.5 g/dL. Meta-analysis showed +31 mL/hr urine output and +1.76 mEq/hr sodium excretion with co-administration. Effect is maximal at 6–8 hours and diminishes by 24 hours.

Spot Urine Sodium: The Yale Diuretic Index

Spot Urine Sodium After IV Furosemide

Obtain spot urine Na 1–2 hours after IV loop diuretic administration to assess natriuretic response

>70–100 mmol/L

Normal natriuretic response

Continue current regimen

50–70 mmol/L

Mild resistance

Optimize dose, consider IV

20–50 mmol/L

Moderate resistance

Combination diuretics, escalate

<20 mmol/L

Severe resistance

SNB, consider UF

Clinical Pearl: Spot urine sodium <50–70 mmol/L after loop diuretic strongly correlates with both diuretic resistance and natriuretic peptide resistance, and predicts poor clinical outcomes. This is a practical bedside tool that avoids the need for 24-hour urine collections. A low spot UNa after adequate loop diuretic dosing is an indication to escalate therapy.

Escalation Strategy for Diuretic Resistance

A stepwise approach to overcoming diuretic resistance. Each step builds on the prior if natriuretic response remains inadequate (spot UNa <50–70 mmol/L).

Step 1: Dose Optimization

  • Convert oral to IV (bypasses gut edema)
  • IV furosemide: 40–80 mg bolus (naive); up to 200 mg bolus (chronic diuretic use)
  • Dose must exceed the diuretic threshold to achieve natriuresis
  • Consider bumetanide or torsemide if furosemide response is poor
  • Continuous infusion: initial bolus then 5–40 mg/hr furosemide (avoids post-dose reabsorption)

Step 2: Combination Therapy (Sequential Nephron Blockade)

  • Add thiazide: Metolazone 2.5–10 mg PO or chlorothiazide 250–500 mg IV 30 min before loop diuretic
  • Mechanism: Blocks compensatory Na reabsorption in distal convoluted tubule (addresses braking phenomenon)
  • Add MRA: Spironolactone 25–50 mg to block aldosterone-mediated collecting duct Na retention
  • Warning: Combination therapy causes profound electrolyte losses (K, Mg, Na) — monitor q6–12h

Step 3: Sequential Nephron Blockade (SNB) — Triple Therapy

  • Loop diuretic + thiazide + MRA = blockade at 3 nephron segments
  • Add acetazolamide (250–500 mg IV) for proximal tubule blockade (ADVOR trial: improved decongestion)
  • Consider IV albumin co-administration if albumin <2.5 g/dL

Step 4: Adjunctive Strategies

  • Hypertonic saline (3% NaCl): 150 mL bolus with furosemide; increases renal perfusion pressure and osmotic gradient
  • Low-dose dopamine: 2–5 mcg/kg/min (renal dose); limited evidence but may improve diuretic response
  • SGLT2 inhibitors: Osmotic diuresis via proximal tubule glucosuria; additive to loop diuretics
  • Aquaphoresis: Tolvaptan (V2 antagonist) for hypervolemic hyponatremia; free water clearance without Na loss

Step 5: Mechanical Fluid Removal

  • Ultrafiltration (UF): Extracorporeal removal of isotonic fluid; bypasses all pharmacologic resistance mechanisms
  • Indicated when pharmacologic strategies fail or severe cardiorenal syndrome limits diuretic efficacy
  • CARRESS-HF trial: UF not superior to pharmacologic therapy as first-line and associated with more adverse events
  • Peritoneal dialysis: Consider for chronic refractory fluid overload; gentle, continuous UF
  • Hemodialysis/CRRT: For refractory fluid overload with concurrent severe AKI or ESKD
ADVOR Trial (2023): Addition of IV acetazolamide 500 mg daily to IV loop diuretics in ADHF improved decongestion at 3 days (42.2% vs 30.5% achieved successful decongestion, OR 1.46). Acetazolamide blocks proximal tubule NHE3 and carbonic anhydrase, reducing proximal Na reabsorption, thereby increasing Na delivery to loop of Henle where loop diuretics act.

Volume Assessment in Heart Failure

Accurate assessment of volume status is essential for guiding diuretic therapy. No single parameter is sufficient; integrate multiple data points.

Assessment Tool What It Tells You Limitations
JVP (Jugular Venous Pressure) Elevated JVP (>8 cm H2O) indicates right-sided volume overload and elevated CVP. Most specific bedside sign of congestion. Difficult in obese patients; requires proper positioning (45 degrees); cannot assess intravascular volume directly
BNP / NT-proBNP Trajectory Rising = worsening congestion/wall stress; falling = successful decongestion. More useful as a trend than single value. Affected by obesity (lower), renal failure (higher), age, AF. BNP rises with ARNI (use NT-proBNP instead). Day-to-day variation 15–20%.
Daily Weights Most practical marker of fluid balance. 1 kg = approximately 1 L fluid. Target 0.5–1 kg/day loss during active decongestion. Scale accuracy, timing consistency, dietary Na intake affects weight independent of volume
Strict I&O Net negative fluid balance target during ADHF. Monitors diuretic response quantitatively. Nursing accuracy variable; insensible losses not captured; cannot distinguish vascular from interstitial fluid removal
Spot Urine Sodium Post-diuretic UNa >70 mmol/L indicates adequate natriuretic response. Low UNa (<50) signals diuretic resistance. Single time point; requires knowledge of when diuretic was given; dietary Na intake can confound
Physical Exam Peripheral edema, lung crackles (often absent in chronic HF), hepatomegaly, ascites, S3 gallop, orthopnea Peripheral edema is a late sign; lung crackles may be absent in chronic compensated HF due to lymphatic drainage adaptation
Point-of-Care Ultrasound IVC collapsibility (>50% = likely euvolemic); lung B-lines (correlate with extravascular lung water); pleural effusions Operator dependent; IVC less reliable with mechanical ventilation or high PEEP
Hemoconcentration Rising hemoglobin/hematocrit during diuresis suggests effective intravascular volume reduction (plasma water removal exceeds RBC removal) Confounded by anemia, transfusions, bleeding; insensitive
Lung Crackles Myth: Absence of lung crackles does NOT exclude pulmonary congestion in chronic HF. Chronic lymphatic drainage adaptation can clear alveolar fluid even with elevated PCWP. Use BNP trajectory, daily weights, and JVP as more reliable markers of congestion.

Guideline-Directed Medical Therapy in Cardiorenal Disease

The four pillars of HFrEF therapy all have cardiorenal implications. GDMT should be optimized even in the setting of CKD, though dose adjustments may be needed.

ARNI / ACEi / ARB

Preferred: ARNI (sacubitril/valsartan)

20% reduction in CV death/HF hospitalization vs. enalapril (PARADIGM-HF)

CKD note: Dose-adjust for eGFR; ACEi > ARB for mortality if ARNI unavailable. Monitor K and Cr after initiation.

Beta-Blocker

Carvedilol, metoprolol succinate, bisoprolol

Counter SNS overactivation; improve survival

CKD note: No dose adjustment needed. Avoid initiation during acute decompensation.

MRA

Spironolactone (HFrEF), finerenone (HFpEF/DKD)

RALES: 30% mortality reduction; FINEARTS-HF: benefit in HFpEF

CKD note: nsMRA (finerenone) preferred with eGFR 30–60 due to lower hyperkalemia risk. Monitor K closely.

SGLT2 Inhibitor

Dapagliflozin, empagliflozin

Cardiorenal protection in HFrEF, HFpEF, and CKD

CKD note: Can initiate with eGFR ≥20; continue until dialysis. Hemodynamic benefit occurs within days. Additive diuretic effect.

Special Considerations in Cardiorenal Disease

Scenario Approach
Rising Cr during decongestion Often acceptable ("permissive AKI") if the patient is clearly congested. Venous congestion relief may improve renal function. Check if Cr rise is from effective decongestion vs. true renal injury (hemoconcentration suggests the former).
Hyperkalemia limiting RAAS blockade Consider nsMRA (finerenone) instead of spironolactone; add patiromer or SZC as K binders; SGLT2i may lower K. Do not withhold RAAS blockers reflexively—mortality benefit outweighs mild hyperkalemia risk.
Hyponatremia in HF Dilutional (hypervolemic) from ADH excess. Restrict free water, optimize decongestion. Tolvaptan for symptomatic hyponatremia. Na <130 predicts poor prognosis.
eGFR <30 mL/min/1.73m² SGLT2i can be initiated down to eGFR 20. ARNI requires dose reduction. Loop diuretics require higher doses (furosemide 80–200 mg IV). Higher doses of thiazides needed (metolazone retains efficacy in advanced CKD).

When to Refer to Advanced HF / Mechanical Support

Recognize the patient who has exhausted medical options and may benefit from advanced therapies.

Triggers for Advanced HF Referral

  • ≥2 HF hospitalizations in 12 months
  • Progressive decline in eGFR with worsening HF
  • Need for IV inotropes for hemodynamic support
  • Persistent NYHA Class III–IV despite optimized GDMT
  • Peak VO2 <14 mL/kg/min on CPET
  • Rising NT-proBNP despite therapy optimization
  • Recurrent ICD shocks for ventricular arrhythmias
  • Diuretic-refractory congestion requiring repeated UF

Advanced Therapies

  • Heart transplantation: Gold standard for eligible patients; limited by donor availability
  • LVAD (Left Ventricular Assist Device): Bridge to transplant or destination therapy; improves CO and renal perfusion
  • Temporary MCS: Impella, ECMO for cardiogenic shock as bridge to recovery or decision
  • Cardiac resynchronization therapy (CRT): For LBBB with QRS ≥150 ms and EF ≤35%
  • Palliative care / hospice: When advanced therapies are not appropriate; focus on symptom management and quality of life
INTERMACS Profiles: Advanced HF patients are classified by hemodynamic severity (Profile 1 = critical cardiogenic shock through Profile 7 = advanced NYHA III). Profiles 1–3 warrant urgent advanced HF evaluation. Early referral improves outcomes—do not wait until the patient is INTERMACS 1 (crash and burn).

References

  1. Ronco C, Haapio M, House AA, et al. Cardiorenal syndrome. J Am Coll Cardiol. 2008;52(19):1527-1539. PubMed
  2. Mullens W, Damman K, Harjola VP, et al. The use of diuretics in heart failure with congestion. Eur Heart J. 2019;40(33):2797-2803. PubMed
  3. Ellison DH, Felker GM. Diuretic therapy for patients with heart failure: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020;75(10):1178-1195. PubMed
  4. Mullens W, Dauw J, Martens P, et al. Acetazolamide in acute decompensated heart failure with volume overload (ADVOR). N Engl J Med. 2022;387(13):1185-1195. PubMed
  5. Bart BA, Goldsmith SR, Lee KL, et al. Ultrafiltration in decompensated heart failure with cardiorenal syndrome (CARRESS-HF). N Engl J Med. 2012;367(24):2296-2304. PubMed
  6. Verbrugge FH, Mullens W, Malbrain MLNG, et al. Renal compression in heart failure: the renal tamponade hypothesis. JACC Heart Fail. 2022;10(3):175-183. PubMed
  7. McMurray JJV, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure (PARADIGM-HF). N Engl J Med. 2014;371(11):993-1004. PubMed
  8. Lee TH, Kuo G, Chang CH, et al. Diuretic effect of co-administration of furosemide and albumin: an updated systematic review and meta-analysis. PLoS One. 2021;16(12):e0260312. PubMed
  9. Ikeda Y, Ishii S, Yazaki M, et al. Association between intestinal oedema and oral loop diuretic resistance in hospitalized patients with acute heart failure. ESC Heart Fail. 2021;8(5):4059-4066. PubMed
  10. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure. J Am Coll Cardiol. 2022;79(17):e263-e421. PubMed
  11. Damman K, Testani JM. The kidney in heart failure: an update. Eur Heart J. 2015;36(23):1437-1444. PubMed
  12. Mullens W, Martens P, Brulé L, et al. Focus on renal congestion in heart failure. Clin Kidney J. 2016;9(1):39-47. PubMed

Andrew Bland, MD, MBA, MS | University of Dubuque PA Program | Urine Nephrology Now

© 2025 | For educational purposes only